Controlled attenuation parameter using the FibroScan® XL probe for quantification of hepatic steatosis for non-alcoholic fatty liver disease in an Asian population

United European Gastroenterology Journal

Volumn 5, Issue 1, 2017, Pages 76-85

  Chan, Wah Kheong ^a   Nik Mustapha, Nik Raihan ^b   Wong, Grace Lai Hung ^c   Wong, Vincent Wai Sun ^c   Mahadeva, Sanjiv ^a  

^a UNIVERSITY OF MALAYA   (Malaysia)

^b HOSPITAL SULTANAH BAHIYAH   (Malaysia)

^c CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

CAP; controlled attenuation parameter; FibroScan; fibrosis; liver stiffness measurement; LSM; NAFLD; Non alcoholic fatty liver disease; steatosis; XL probe

Indexed keywords

ADULT; ARTICLE; BODY MASS; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; ECHOGRAPHY; ELASTOGRAPHY; FATTY LIVER; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INFLAMMATION; LIVER BIOPSY; LIVER FIBROSIS; LIVER STIFFNESS; MAJOR CLINICAL STUDY; MALE; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; TRANSIENT ELASTOGRAPHY;

EID: 85011602148     PISSN: 20506406     EISSN: 20506414     Source Type: Journal    
DOI: 10.1177/2050640616646528     Document Type: Article

References (35)

1. Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of non-alcoholic fatty liver disease—meta-analytic assessment of prevalence, incidence and outcomes. Hepatology. Epub ahead of print 28 December 2015. DOI: 10.1002/hep.28431
2. Wong VW, Chu WC, Wong GL. Prevalence of non-alcoholic fatty liver disease and advanced fibrosis in Hong Kong Chinese: A population study using proton-magnetic resonance spectroscopy and transient elastography. Gut 2012; 61: 409–415.
3. Goh SC, Ho EL, Goh KL. Prevalence and risk factors of non-alcoholic fatty liver disease in a multiracial suburban Asian population in Malaysia. Hepatol Int 2013; 7: 548–554.
4. Chan WK, Tan AT, Vethakkan SR. Non-alcoholic fatty liver disease in diabetics—prevalence and predictive factors in a multiracial hospital clinic population in Malaysia. J Gastroenterol Hepatol 2013; 28: 1375–1383.
5. Chan WK, Bahar N, Razlan H. Non-alcoholic fatty liver disease in a young multiracial Asian population—a worrying ethnic predilection in Malay and Indian males. Hepatol Int 2014; 8: 121–127.
6. Yoneda M, Yoneda M, Fujita K. Transient elastography in patients with non-alcoholic fatty liver disease (NAFLD). Gut 2007; 56: 1330–1331.
7. Sasso M, Beaugrand M, de Lédinghen V. Controlled attenuation parameter (CAP): A novel VCTE guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis: Preliminary study and validation in a cohort of patients with chronic liver disease from various causes. Ultrasound Med Biol 2010; 36: 1825–1835.
8. Chan WK, Nik Mustapha NR, Mahadeva S. Controlled attenuation parameter for the detection and quantification of hepatic steatosis in nonalcoholic fatty liver disease. J Gastroenterol Hepatol 2014; 29: 1470–1476.
9. Myers RP, Pomier-Layrargues G, Kirsch R. Feasibility and diagnostic performance of the FibroScan XL probe for liver stiffness measurement in overweight and obese patients. Hepatology 2012; 55: 199–208.
10. Sasso M, Audière S, Kemgang A. Liver steatosis assessed by controlled attenuation parameter (CAP) measured with the XL probe of the FibroScan: A pilot study assessing diagnostic accuracy. Ultrasound Med Bio 2016; 42: 92–103.
11. Chalasani N, Younossi Z, Lavine JE. The diagnosis and management of non-alcoholic fatty liver disease: Practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Am J Gastroenterol 2012; 107: 811–826.
12. Anuurad E, Shiwaku K, Nogi A. The new BMI criteria for Asians by the regional office for the western pacific region of WHO are suitable for screening of overweight to prevent metabolic syndrome in elder Japanese workers. J Occup Health 2003; 45: 335–343.
13. Alberti KG, Zimmet P, Shaw J. The metabolic syndrome—a new worldwide definition. Lancet 2005; 366: 1059–1062.
14. Kleiner DE, Brunt EM, Van Natta M. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41: 1313–1321.
15. Boursier J, Zarski JP, de Lédinghen V. Determination of reliability criteria for liver stiffness evaluation by transient elastography. Hepatology 2013; 57: 1182–1191.
16. Velussi M, Cernigoi AM, De Monte A. Long-term (12 months) treatment with an anti-oxidant drug (silymarin) is effective on hyperinsulinemia, exogenous insulin need and malondialdehyde levels in cirrhotic diabetic patients. J Hepatol 1997; 26: 871–879.
17. Myers RP, Pollett A, Kirsch R. Controlled attenuation parameter (CAP): A noninvasive method for the detection of hepatic steatosis based on transient elastography. Liver Int 2012; 32: 902–910.
18. Sasso M, Tengher-Barna I, Ziol M. Novel controlled attenuation parameter for noninvasive assessment of steatosis using Fibroscan(®): Validation in chronic hepatitis C. J Viral Hepat 2012; 19: 244–253.
19. de Lédinghen V, Vergniol J, Foucher J. Non-invasive diagnosis of liver steatosis using controlled attenuation parameter (CAP) and transient elastography. Liver Int 2012; 32: 911–918.
20. Kumar M, Rastogi A, Singh T. Controlled attenuation parameter for non-invasive assessment of hepatic steatosis: Does etiology affect performance? J Gastroenterol Hepatol 2013; 28: 1194–1201.
21. Masaki K, Takaki S, Hyogo H. Utility of controlled attenuation parameter measurement for assessing liver steatosis in Japanese patients with chronic liver diseases. Hepatol Res 2013; 43: 1182–1189.
22. Chon YE, Jung KS, Kim SU. Controlled attenuation parameter (CAP) for detection of hepatic steatosis in patients with chronic liver diseases: A prospective study of a native Korean population. Liver Int 2014; 34: 102–109.
23. Yilmaz Y, Yesil A, Gerin F. Detection of hepatic steatosis using the controlled attenuation parameter: A comparative study with liver biopsy. Scand J Gastroenterol 2014; 49: 611–616.
24. Shen F, Zheng RD, Mi YQ. Controlled attenuation parameter for non-invasive assessment of hepatic steatosis in Chinese patients. World J Gastroenterol 2014; 20: 4702–4711.
25. Karlas T, Petroff D, Garnov N. Non-invasive assessment of hepatic steatosis in patients with NAFLD using controlled attenuation parameter and 1H-MR spectroscopy. PLoS One 2014; 9: e91987–e91987.
26. de Lédinghen V, Vergniol J, Capdepont M. Controlled attenuation parameter (CAP) for the diagnosis of steatosis: A prospective study of 5323 examinations. J Hepatol 2014; 60: 1026–1031.
27. Ferraioli G, Tinelli C, Lissandrin R. Controlled attenuation parameter for evaluating liver steatosis in chronic viral hepatitis. World J Gastroenterol 2014; 20: 6626–6631.
28. Jung KS, Kim BK, Kim SU. Factors affecting the accuracy of controlled attenuation parameter (CAP) in assessing hepatic steatosis in patients with chronic liver disease. PLoS One 2014; 9: e98689–e98689.
29. Wang CY, Lu W, Hu DS. Diagnostic value of controlled attenuation parameter for liver steatosis in patients with chronic hepatitis B. World J Gastroenterol 2014; 20: 10585–10590.
30. Lupsor-Platon M, Feier D, Stefănescu H. Diagnostic accuracy of controlled attenuation parameter measured by transient elastography for the non-invasive assessment of liver steatosis: A prospective study. J Gastrointestin Liver Dis 2015; 24: 35–42.
31. Mi YQ, Shi QY, Xu L. Controlled attenuation parameter for noninvasive assessment of hepatic steatosis using Fibroscan®: Validation in chronic hepatitis B. Dig Dis Sci 2015; 60: 243–251.
32. Shen F, Zheng RD, Shi JP. Impact of skin capsular distance on the performance of controlled attenuation parameter in patients with chronic liver disease. Liver Int 2015; 35: 2392–2400.
33. Wong VW, Vergniol J, Wong GL. Liver stiffness measurement using XL probe in patients with nonalcoholic fatty liver disease. Am J Gastroenterol 2012; 107: 1862–1871.
34. Musso G, Gambino R, Cassader M. Meta-analysis: Natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med 2011; 43: 617–649.
35. Chan WK, Nik Mustapha NR, Mahadeva S. A novel 2-step approach combining the NAFLD fibrosis score and liver stiffness measurement for predicting advanced fibrosis. Hepatol Int 2015; 9: 594–602.